Understand the source comparison
Best Peptides for Lupus Treatment: Research Model Comparison
| Peptide | Primary Mechanism | Lupus-Relevant Pathway | Studied Dosage Range | Half-Life | Bottom Line ||—|—|—|—|—|| Thymalin | Thymic T-cell regulation | Restores central tolerance; reduces autoreactive T-cell activation | 5–20 mg IM weekly | 18–24 hours | B
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- | Peptide | Primary Mechanism | Lupus-Relevant Pathway | Studied Dosage Range | Half-Life | Bottom Line ||—|—|—|—|—|| Thymalin | Thymic T-cell regulation | Restores central tolerance; reduces autoreactive T-cell activation | 5–20 mg IM weekly | 18–24 hours | Best evidence for reducing ANA titers and shifting immune tolerance. Targets root thymic dysfunction || BPC-157 | VEGF/FGF upregulation | Accelerates tissue repair in nephritis and vasculitis models | 10–500 mcg/kg daily | 4–6 hours | Most studied for lupus nephritis repair. Doesn't stop immune attack but speeds recovery || KPV | NF-κB inhibition | Blocks cytokine transcription during flares | 1–5 mg/kg SC | <30 minutes | Strongest anti-inflammatory signal without broad immunosuppression. Short half-life limits practicality || Thymosin Alpha-1 | TLR modulation | Reduces dendritic cell presentation of self-antigens | 1.6 mg SC twice weekly | 2–3 hours | Component of Thymalin; standalone use in viral contexts but limited lupus-specif